Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians.
about
Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive ReviewPharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical UsePrognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patientsPolymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.Polymorphisms of uridine glucuronosyltransferase gene and irinotecan toxicity: low dose does not protect from toxicity.New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targetsAn internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patientsIdentification of Promotor and Exonic Variations, and Functional Characterization of a Splice Site Mutation in Indian Patients with Unconjugated Hyperbilirubinemia.Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRIPersonalized medicine and the clinical laboratory.Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trialClinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testingUGT1A1 polymorphisms in cancer: impact on irinotecan treatment.Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy.UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases.Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer.Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis.The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.Effect of UDP-Glucuronosyltransferase (UGT) 1A Polymorphism (rs8330 and rs10929303) on Glucuronidation Status of AcetaminophenThe impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.Unconjugated hyperbilirubinemia: a blessing in disguise?The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer.A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101).SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand.
P2860
Q26768483-418D19BF-CDFD-43CC-B400-239C9F317097Q28068930-2E0A17D5-671D-4EC2-98E5-6B4E5C8EAAA8Q33413622-AC727EB5-4689-4BB3-B6D9-EFC5D3CE3459Q33434697-89D0CD23-17D9-41F4-97CB-35F2066450D8Q33604248-C173A43A-5DF5-455A-830B-F0C54785C05CQ33731804-6AD57248-E3A6-4FBB-A44D-8E31D75F4835Q35603648-7228EABC-EAC5-4E53-9A4E-CB60BE5C2993Q35881663-DCC224E3-2397-420D-A23D-015BD4C99851Q35903844-CB332B2A-2365-4752-820B-BE4A3EAD8165Q36916966-3C17B56F-DDD4-4781-902E-2FEC5C949602Q37632102-51C0C3A1-2B79-4EAC-85B3-93FE574A7F2FQ37652863-5C4E737B-2987-4AB6-A842-1203ED2A0D20Q37682812-A68775CE-AC82-4808-B0BA-647929AC0CE6Q37726433-AD638C09-A3FB-414A-ACCA-A7AB089E4E8AQ38393997-049155E5-9912-4696-B019-6216B4709152Q38495339-4002B428-AC9A-4450-81DF-7130DB06BF12Q38626609-D10973F6-A399-481D-8FE1-5DB4C212CC13Q38827826-77353413-CD54-4A60-B30D-447BF8C1125FQ38843097-CFF1EE61-3CE6-4A76-97B0-603001BD1431Q38922471-2878BA85-80E4-4482-BAF0-14C223F107D6Q41078858-C860C665-005F-443B-926C-9EEAD963C51EQ42360755-318050FB-54E2-4252-9B3C-D5317594D5F8Q43358640-1D53783F-4C08-4CB3-8C77-F6498D52C11EQ43525854-188697A0-51EA-43F5-A115-3D38FC067B21Q48027272-25E87942-F6A2-4C0A-902F-74E35BF7865EQ52362144-241B2EB4-1CD7-4214-922B-4622F8EC1FFBQ52682270-03E726FE-82A4-411A-8442-0A134F3306CFQ53280262-C7879CF9-2123-4E23-8182-D8481D38F093Q55497899-D893AA73-9236-492F-970F-32CC93611367
P2860
Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Association of UGT1A1*28 polym ...... a meta-analysis in Caucasians.
@en
Association of UGT1A1*28 polym ...... a meta-analysis in Caucasians.
@nl
type
label
Association of UGT1A1*28 polym ...... a meta-analysis in Caucasians.
@en
Association of UGT1A1*28 polym ...... a meta-analysis in Caucasians.
@nl
prefLabel
Association of UGT1A1*28 polym ...... a meta-analysis in Caucasians.
@en
Association of UGT1A1*28 polym ...... a meta-analysis in Caucasians.
@nl
P2093
P2860
P356
P1476
Association of UGT1A1*28 polym ...... a meta-analysis in Caucasians.
@en
P2093
P2860
P2888
P304
P356
10.1038/TPJ.2013.10
P50
P577
2013-03-26T00:00:00Z